All posts by medical

Lilly and Incyte Announce Positive Top-Line Results from the North American Phase 3 Study (BREEZE-AD5) of Oral Selective JAK Inhibitor Baricitinib in…

TORONTO, Feb. 11, 2020 (GLOBE NEWSWIRE) -- Eli Lilly and Company and Incyte announced that baricitinib met the primary endpoint in BREEZE-AD5, an investigational Phase 3, randomized, placebo-controlled study evaluating the safety and efficacy of baricitinib for the treatment of adult patients with moderate- to severe atopic dermatitis (AD). The primary endpoint was defined by the proportion of patients achieving at least a 75% or greater change from baseline in their Eczema Area and Severity Index (EASI) at Week 16.

"Atopic dermatitis is chronic skin condition which affects approximately one to three percent of adults worldwide.6 We appreciate the distressing impact this condition can have on a person's quality of life and the need for additional treatment options," says Dr. Doron Sagman, Vice President, R&D and Medical Affairs, Eli Lilly Canada. "We are pleased that baricitinib met the primary endpoint in the BREEZE-AD5 study, and we will continue to focus on patient-centered solutions."

BREEZE-AD5 is a multicenter, double-blind, randomized, placebo-controlled study designed for and conducted in North America and which evaluated the efficacy and safety of the 1-mg and 2-mg doses of baricitinib monotherapy for the treatment of adult patients with moderate- to severe AD. In this study, the 2-mg dose of baricitinib met the primary endpoint as defined by the proportion of participants achieving EASI75 at Week 16. Baricitinib also met key secondary endpoints including another measure of skin inflammation defined by clear or almost clear skin and at least 2 points improvement on the validated Investigator's Global Assessment for AD (vIGA 0 or 1 at Week 16), and it reduced itch severity.

P n.s. * P 0.05, and *** P 0.001 for baricitinib compared to placebo by analysis unadjusted for multiplicity. Non-responder imputation upon rescue with Topical corticosteroid (TCS). avIGA = validated Investigator's Global Assessment.

The safety profile in BREEZE-AD5 was consistent with the known safety findings of baricitinib in AD. The most common treatment-emergent adverse events (TEAEs) included upper respiratory tract infections, nasopharyngitis, and diarrhea. No venous thromboembolic events (VTEs) or deaths were reported in the trial. The full results from the BREEZE-AD5 study will be disclosed at future scientific venues and in peer-reviewed journals.

"These positive top-line results show that baricitinib could be an effective treatment option for patients living with moderate- to severe AD whose needs have remained unmet," says Dr. Gooderham, Dermatologist and study investigator.

About BREEZE-AD5BREEZE-AD5, a multicenter, double-blind, randomized, placebo-controlled, Phase 3 study in adult patients with moderate- to severe atopic dermatitis (AD). BREEZE-AD5, which was designed for and conducted in North America, evaluated the efficacy and safety of the 1-mg and 2-mg doses of baricitinib monotherapy for the treatment of adult patients with moderate to severe AD. The primary endpoint was defined by the proportion of participants achieving Eczema Area and Severity Index 75 (EASI75) at Week 16. BREEZE-AD5 completes the read out from the BREEZE development program, following the recent topline results from BREEZE-AD4. BREEZE-AD1, -AD2 and -AD7 results were disclosed in 2019.

About OLUMIANTOLUMIANT (baricitinib), in combination with methotrexate (MTX), is indicated for reducing the signs and symptoms of moderate- to severe rheumatoid arthritis (RA) in adult patients who have responded inadequately to one or more disease-modifying anti-rheumatic drugs (DMARDs). OLUMIANT can be used as a monotherapy in cases of intolerance to MTX.1

OLUMIANT is believed to interfere with the activity of an enzyme called Janus Kinase (JAK). Normally JAK enzymes help turn on your immune system when you need it. The immune system then causes swelling and tenderness. This is called inflammation. There are four known JAK enzymes: JAK1, JAK2, JAK3 and TYK2. JAK-dependent cytokines have been implicated in the pathogenesis of a number of inflammatory and autoimmune diseases.1 OLUMIANT has greater inhibitory potency at JAK1, JAK2 and TYK2 relative to JAK3; however, the relevance of inhibition of specific JAK enzymes to therapeutic effectiveness is not currently known.

About Atopic DermatitisAtopic dermatitis (AD), or atopic eczema, is a chronic, relapsing skin disease characterized by intense itching, dry skin and inflammation that can be present on any part of the body.2 AD is a heterogeneous disease both clinically and biologically, but may be characterized by chronic baseline symptoms of itch, redness and skin damage that are often punctuated with episodic, sometimes unpredictable, flares or exacerbations.3,4 AD affects approximately 1-3% of adults worldwide.5

Moderate- to severe AD is characterized by intense itching, resulting in visibly damaged skin.6 Like other chronic inflammatory diseases, AD is immune-mediated and involves a complex interplay of immune cells and inflammatory cytokines.7

About Lilly in DermatologyBy following the science through unchartered territory, we continue Lilly's legacy of delivering innovative medicines that address unmet needs and have significant impacts on people's lives around the world. Skin-related diseases are more than skin deep. We understand the devastating impact this can have on people's lives. At Lilly, we are relentlessly pursuing a robust dermatology pipeline to provide innovative, patient-centered solutions so patients with skin-related diseases can aspire to live life without limitations.

About Eli Lilly CanadaEli Lilly and Company is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by Colonel Eli Lilly, who was committed to creating high quality medicines that meet people's needs, and today we remain true to that mission in all our work. Lilly employees work to discover and bring life-changing medicines to people who need them, improve the understanding and management of disease, and contribute to our communities through philanthropy and volunteerism.

Eli Lilly Canada was established in 1938, the result of a research collaboration with scientists at the University of Toronto, which eventually produced the world's first commercially-available insulin. Our work focuses on oncology, diabetes, autoimmunity, neurodegeneration, and pain. To learn more about Lilly Canada, please visit us at http://www.lilly.ca.

For our perspective on issues in healthcare and innovation, follow us on twitter @LillyPadCA

About IncyteIncyteis aWilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics. For additional information onIncyte, please visit Incyte.com and follow @Incyte.

Media Contact: Samira RehmanRehman_Samira@lilly.com 647-617-1994

REFERENCES

1 OLUMIANT Product Monograph2 Zuberbier T, Orlow SJ, Paller AS, et al. Patient perspectives on the management of atopic dermatitis. The Journal of Allergy and Clinical Immunology. 2006;118: 226-32.3 Thijs JL, Strickland I, Bruijnzeel-Koomen C, et. al. Moving toward endotypes in atopic dermatitis: identification of patient clusters based on serum biomarker analysis. The Journal of Allergy and Clinical Immunology. 2017.4 Langan SM, Thomas KS, Williams HC. What is meant by "flare" in atopic dermatitis? A systematic review and proposal. Arch Dermatol. 2006;142:1190-1196.5 Nutten S. Atopic dermatitis: global epidemiology and risk factors. Annals of Nutrition and Metabolism. 2015;66(suppl 1): 8-16.6 Yosipovitch G, Papoiu AD. What causes itch in atopic dermatitis? Current Allergy and Asthma Reports. 2008;8:306-311.7 Weidinger, S, Novak, N. Atopic dermatitis. The Lancet Volume 387. 2016;10023:1109-1122.

Read the original here:
Lilly and Incyte Announce Positive Top-Line Results from the North American Phase 3 Study (BREEZE-AD5) of Oral Selective JAK Inhibitor Baricitinib in...

The Neuroscience of Friendship – The American Prospect

The Open Mindexplores the world of ideas across politics, media, science, technology, and the arts.The American Prospectis republishing this excerpt.

Alexander Heffner: We need more friends in our lives today in this digital environment.

Lydia Denworth: We do. As a science writer I mostly cover the brain. What neuroscience is mainly interested in these days is mapping connections in the brain and inside the brain. I went to a meeting about social neuroscience, which is a sort of newer field within neuroscience, that is about mapping connections in and outside of the brain, this kind of web of connections that we have with other people. I sat there at this meeting listening to them talking about all these elements of social behavior and what it does in the brain.

I was right at that moment sort of wedged in between a parent with Alzheimers disease and teenagers. So I was very buffeted day in day out by other peoples emotions and ups and downs. It made me think about the ways that people in our lives affect us, even our biology, the way they make your pulse pound and your adrenaline spike.

But then I also thought about here I am losing my parents and my kids are growing up and out: I better make sure Ive got my friends. Thats one of the big topics that social neuroscience gets intothats really how I came to it. It was that kind of confluence of my personal life and the work I was already doing.

Heffner: You are giving rebirth to this science in the book and youre acknowledging that friendship revitalizes us.

Denworth: Right. The newest part of the science is the biology, this question of how is it that a social relationship, which is not like food that you actually put in your body or exercise where youre moving your muscles and you can understand why going for a run might affect your blood pressure. But why is it that a conversation with a good friend sort of gets inside your body and changes the way your body works? I mean it literally affects your blood pressure, your sleep, your stress responses, your immune system, all of those things.

Friendship for a long time was not studied seriously by biologists, anyway, because its very hard to measure. Its hard to defineand science is all about measurement and definition. You need to know what it is youre trying to measure in order to sort of make a statement about it. While friendship in human society has a lot of cultural aspects to it, and its not entirely cultural and thats the way people imagined it for a long time. C.S. Lewis, the famous writer, he said, you know, friendship has no survival value, but it gives value to survival. In people, but also in other species, those with the strongest social bonds live longest, have the most reproductive success, which is the evolutionary measure that you want.

Heffner: Thats one thing that really struck me about the book and the subject because we are in this climate of increasing domestic terrorism, and, of course, lone wolf attacks where there are stories after stories of assassins who have massacred people because they were not, they didnt have friends. So we need to understand the science of how we can relate socially to rebuild capital, social capital.

Denworth: It is so distressing to see these people who are so unconnected and or they think theyre connecting online with people who think like they do. But that is so different from what real true friendship is. But, you know, were not stupid. We know that our Facebook friend that we actually never see, you know, havent seen in years is not the same thing as your best friend that you call when something good or bad happens in your life. I am sure that kids who really feel connected are just much less likely to go down that path.

We need to understand, with children anyway, often we are pushing them to accomplish things and they seem obsessed with their friends. And as a parent we sometimes say, well, okay, your friends are great, but you know, you need to do this. Thats not untrue at times, but I do think its really important to stop and check ourselves and say, wait a minute, are we making sure that they are building relationships that they need?

Heffner: You said two things that interest me greatly. One is about feeling connected and the other is about friendships outside of the family.

Denworth: This new science of friendship both blurs the lines between family and friends and also helps us to try to understand the differences. So, the word friend is qualitative, right, its, its about a relationship and emotion. And it tells you if I call someone a friend, it tells you something about how I feel about them. It should. And if I, you know, refer to my husband or my son or my siblings, that those words are, theyre categorical. They tell you how were connected.

But they dont actually tell you anything about the quality of our relationship, which is why when people like to say that their spouse is their best friend but they do that specifically to tell you that their marriage is good.

Heffner: Qualitatively, right?

Denworth: Qualitatively, exactly. To add to what you know about that marriage. And the truth is that marriage can, your spouse can be your best friend, but, also not, sadly in a bunch of cases. And, and in fact it for a long time we didnt aspire to have our spouse be our best friend, you know, so but one of the things that is really important is quality. Thats why friendship can be a template for all other relationships because when you think of your closest friends, you really think about the positive, the way that you treat each other positively.

Heffner: Unfortunately, there are those who would feel connected by virtue of tribe only. When I mentioned the rise of bigotry and new racism, the new Jim Crow in this country, folks unfortunately can feel connected on chat rooms and then go out and massacre people because theyre not their same race or from the same country theyre from.

Denworth: The work on the neuroscience of empathy speaks to what youre talking about here. Which is that first of all, we understand now that theyre there in many ways theres positive elements of empathy. When we think of empathy, we think of it as a good thing, but it also carries with it that kind of us/them that, that, in-group and out-group sort of element and, and you can see it. What I hope is that understanding how our brains work and that we do bring implicit bias, all of us into the world. Theres a lot of research that shows that then you have to be aware of it and then you have to work to counter it a little bit.

Heffner: In this political climate there, people often riff on the strength of their friendship and whether or not politics can get in the way. I was wondering if thats something that you grappled with, the fact that sometimes you need a base level of values.

Denworth: Of values, you do. In fact, I think one of the really interesting things is that worldview is one of the things that most draws us together with, with someone else.

Heffner: Where is the research going right now?

Denworth: The neuroscience really intrigues me. Theyre trying to look at the brains of two people as they interact and essentially capture friendship while its happening. The idea is, is there some place that your brains go when youre interacting with a friend that they wouldnt get to on their own? And can we see it? Can we see it in a brain scanner? What we do know is that and just in the last year or two, we know that the way your brain processes the world is more similar to the way your friends brain processes the world than it is to people to whom youre not as close.

The question is, do you and your friend process the world the same way and thats part of what draws you together. I mean, you cant know it; you cant look at someone and say, I see how you are, you know, auditory cortex is operating but you, but you might end up being drawn to each other or do you become more similar as you are together? We dont know the answer yet. Theyre working on that, but its probably a little of both.

See the article here:
The Neuroscience of Friendship - The American Prospect

Neuroscience study finds evidence that meditation increases the entropy of brainwaves – PsyPost

New research suggests that the brain displays a similar pattern of chaotic activity during meditation as it does during the psychedelic experience. The findings, published in the journal Neuroscience, indicate that meditation is associated with increased brain entropy.

We are currently witnessing a major psychedelic renaissance, both in science and society. Psychedelics are being reconsidered as comparatively safe tools to investigate the relationship between brain, mind and consciousness, as well as promising clinical alternatives to treat certain psychiatric disorders, such as depression, explained study author Enzo Tagliazucchi a professor at the University of Buenos Aires and director of the Computational Cognitive Neuroscience Lab.

I became interested in certain overlaps between the phenomenology (i.e. what it feels like) of some meditation traditions and the psychedelic state. For instance, both states have been consistently linked to a collapse of self-boundaries and a merging of the subjective and objective sides of reality.

My colleague Robin Carhart-Harris, one of the leading figures of the psychedelic renaissance, has put forward a theory of the psychedelic state as a brain state of increased entropy, and I became interested in finding out whether meditation could also be associated with increases in the entropy of brain activity.

Brain entropy describes the randomness and predictability of brain activity. Tagliazucchi and Carhart-Harris were previously involved in research which found that people had higher brain entropy meaning a larger range of potential brain states under the influence of the psychedelic drug psilocybin.

Other research has found that higher entropy in several key brain areas is associated with higher intelligence. But heightened brain entropy has also been observed in patients with schizophrenia.

In his new study, Tagliazucchi and his colleagues recorded participants brainwaves to calculate their brain entropy during meditation. Electrical brain activity and oscillation patterns were measured by electroencephalogram in 27 Himalaya Yoga meditators, 20 Vipassana meditators, 27 Isha Yoga meditators, and 30 individuals with no meditation experience.

The researchers found that Vipassana meditation resulted in the highest entropy increases, with the most salient increases occurring in alpha and gamma brainwaves.

In spite of not feeling at all like brain activity, your conscious experience is the result of processes that happen in the brain, and because of this there has to be a correspondence between what happens physically in the brain and how that feels in your first-person point of view, Tagliazucchi told PsyPost.

The acute effects of psychedelics and some meditative practices both lead to states departing from ordinary conscious wakefulness, and are experienced subjectively as richer in information and capable of sustaining an ample repertoire of contents. Because of this, we hypothesized that meditation would be associated with increased information content (in other words, increased entropy) of brain activity recordings, which was confirmed in the study.

Future research could use other tools such as functional magnetic resonance imaging or magnetoencephalography to examine brain entropy during meditation.

We need to replicate this result using other techniques to measure brain activity. We also need to probe the conscious experience of the subjects during or immediately after their meditation practice to verify whether time to time changes in entropy correspond to the fluctuating nature of their subjective experience, Tagliazucchi explained.

The study, Meditation Increases the Entropy of Brain Oscillatory Activity, was authored by Roco Martnez Vivot, Carla Pallavicinia, Federico Zamberlan, Daniel Vigo, and Enzo Tagliazucchi.

See the original post here:
Neuroscience study finds evidence that meditation increases the entropy of brainwaves - PsyPost

CCMB teams follow-up discovery finds mention in ACS Neuroscience journal – The Hindu

In a follow-up discovery published in the American Chemical Society journal, ACS Chemical Neuroscience, Professor Amitabha Chattopadhyays group from the CSIR-Centre for Cellular and Molecular Biology (CCMB) here has now shown that modulating the levels of cholesterol - an important lipid in the cell membrane - could change serotonin1A receptor's internal mechanism.

Serotonin1A receptor is one such important drug target in neuropsychiatric disorders such as anxiety and depression. Its function is regulated inside the cell through a process called endocytosis - a key event in the therapeutic action of several drugs, according to a release.

Cells in the human body body communicate with their surroundings through tiny nano-machines called G Protein-Coupled Receptors (GPCRs) present in its outermost membrane which are major drug targets in almost all clinical areas.

Prof. Chattopadhyays team had previously shown that the serotonin1A receptor regulates through specialized regions of the cell membrane, called clathrin-coated pits, and later recycles into the cell membrane.

When CCMB researchers treated cells with statin - the best-selling cholesterol lowering drug in the market - they observed that the serotonin1A receptor, instead of using its regular clathrin-coated pits, used alternate regions called caveolae. We observed that this switch in the mechanism of internal regulation reverted to clathrin-coated pits when we put back cholesterol in cells without statin treatment, said G. Aditya Kumar, a Ph.D. student and first author of the paper.

Experiments from the team also revealed that receptors that usually recycle back to the cell membrane in normal conditions started getting degraded inside cells when they were treated with statin.

Anti-depressant drugs, termed selective serotonin reuptake inhibitors (SSRIs), target the endocytosis of serotonin1A receptor as their mechanism of action.

These results show cholesterol modulates cells internal mechanism and could provide novel insights into improved therapeutic activity of antidepressant drugs when administered in combination with statins, said Prof. Chattopadhyay.

These studies from CCMB are especially relevant in the Indian context since the National Mental Health Survey (2015-16) reported that more than five per cent of the adult Indian population suffers from depression.

You have reached your limit for free articles this month.

Register to The Hindu for free and get unlimited access for 30 days.

Find mobile-friendly version of articles from the day's newspaper in one easy-to-read list.

Enjoy reading as many articles as you wish without any limitations.

A select list of articles that match your interests and tastes.

Move smoothly between articles as our pages load instantly.

A one-stop-shop for seeing the latest updates, and managing your preferences.

We brief you on the latest and most important developments, three times a day.

Not convinced? Know why you should pay for news.

*Our Digital Subscription plans do not currently include the e-paper ,crossword, iPhone, iPad mobile applications and print. Our plans enhance your reading experience.

Link:
CCMB teams follow-up discovery finds mention in ACS Neuroscience journal - The Hindu

Emotional Analytics Industry to Exhibit a CAGR of 15.6% During 2019-2027 – Biometrics & Neuroscience Technologies are Leading the Market -…

DUBLIN, Feb. 11, 2020 /PRNewswire/ -- The "Global Emotional Analytics Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2019 To 2027" report has been added to ResearchAndMarkets.com's offering.

The global emotional analytics market is expected to expand at a CAGR of 15.6% during the forecast period from 2019 to 2027.

The rising adoption of Big Data analytics and artificial intelligence (AI) are a few of the major factors driving the growth of the emotional analytics market. Emotional Analytics has grown its importance in industries including call centers, sales, and marketing among others. It is often used in call centers as a standalone application or in a customer relationship management system, which uses audio mining techniques and correlation engines to monitor caller's word and emotions.

Based on technology, Biometrics and neuroscience segment is leading the emotional analytics market as it enhances the safeguarding of the business operations. With biometric technology becoming more widespread, enterprises and governments are adopting the technology to create a secure, and fast experience for employees when logging into workplace networks and applications. The rapid adoption and application of emotional analytics are expected to propel the growth of the market.

Based on geography, the emotional analytics market is dominated by the North America region owing to its dominance to the rapid adoption of artificial intelligence technology and Big Data analytics. North America is trailed by Europe as numerous end-user industry verticals such as defense and security agencies and government among others are rapidly adopting emotional analytics software. The increasing adoption of facial biometrics within various industries such as banking, finance, sales, and marketing among others is embarking the growth to a large extent.

Widespread application of Big Data and artificial intelligence are creating broader opportunities for emotional analytics developers. Technology companies involved in developing emotional analytics software are aggressively focusing on the development of advanced emotion detection APIs, facial biometric tools and camera-based analytics platforms among others. For instance, Beyond Verbal an Israeli start-up has developed an engine that measures a person's emotional state based on their vocal intonations. This engine is being used in various call centers and they have seen tremendous growth in their sales after the software's deployment.

Some of the leading manufacturers/developers profiled in the study include Google, Inc., Apple, Inc., Facebook, Inc., Microsoft Corporation, IBM Corporation, Kairos AR, Inc., Affectiva Inc., Beyond Verbal, Eyris (Emovu), iMotions A/S, sensation.io, RealComm Global LLC, Neuromore Inc., Lightspeed LLC, Retinad Virtual Reality Inc. among others.

Key Topics Covered

1. Preface

2. Executive Summary2.1. Global Emotional Analytics Market Snapshot2.2. Global Emotional Analytics Market, by Technology, 2018 (US$ Mn)2.3. Global Emotional Analytics Market, by Application, 2018 (US$ Mn)2.4. Global Emotional Analytics Market, by Type, 2018 (US$ Mn)2.5. Global Emotional Analytics Market, by Solutions, 2018 (US$ Mn)2.6. Global Emotional Analytics Market, by End-use vertical, 2018 (US$ Mn)2.7. Global Emotional Analytics Market, by Geography, 2018 (US$ Mn)

3. Global Emotional Analytics Market Analysis3.1. Global Emotional Analytics Market Overview3.2. Market Inclination Insights3.2.1. Recent Trends3.2.2. Future Outlook3.3. Market Dynamics3.3.1. Market Drivers3.3.2. Market Challenges3.4. Attractive Investment Proposition, by Geography, 20183.5. Competitive Landscape3.5.1. Market Positioning of the Leading Manufacturers3.5.2. Major Strategies Adopted

4. Global Emotional Analytics Market Value, by Technology, 2018 - 2027 (US$ Mn)4.1. Comparative Analysis4.1.1. Emotional Analytics Market Value, by Application, 2018 & 2027 (Value %)4.2. Artificial Intelligence4.3. Biometrics and Neuroscience4.4. 3D Modelling4.5. Pattern Recognition4.6. Records management4.7. Others (Facial Recognition)

5. Global Emotional Analytics Market Value, by Application , 2018 - 2027 (US$ Mn)5.1. Comparative Analysis5.1.1. Emotional Analytics Market Value, by Application, 2018 & 2027 (Value %)5.2. Customer Experience Management5.3. Competitive Intelligence5.4. Sales and Marketing Management

6. Global Emotional Analytics Market Value, by Type, 2018 - 2027 (US$ Mn)6.1. Comparative Analysis6.1.1. Emotional Analytics Market Value, by Solutions, 2018 & 2027 (Value %)6.2. Text6.3. Facial6.4. Speech6.5. Video Analytics

7. Global Emotional Analytics Market Value, by Solutions, 2018 - 2027 (US$ Mn)7.1. API & SDK7.2. Mobile and Web Application7.3. Cloud

8. Global Emotional Analytics Market Value, by End-use vertical, 2018 - 2027 (US$ Mn)8.1. Comparative Analysis8.1.1. Emotional Analytics Market Value, by End-use vertical, 2018 & 2027 (Value %)8.2. Enterprises8.3. Defense and Security agencies8.4. Commercial8.5. Industrial8.6. Others (personal users)

9. North America Emotional Analytics Market Analysis, 2018 - 2027 (US$ Mn)

10. Europe Emotional Analytics Market Analysis, 2018 - 2027 (US$ Mn)

11. Asia-Pacific Emotional Analytics Market Analysis, 2018 - 2027 (US$ Mn)

12. Rest of World Emotional Analytics Market Analysis, 2018 - 2027 (US$ Mn)

13. Company Profiles13.1. Google, Inc.13.2. Apple, Inc.13.3. Facebook, Inc.13.4. Microsoft Corporation13.5. IBM Corporation13.6. Kairos AR Inc.13.7. Affectiva Inc.13.8. Beyond Verbal13.9. Eyris (Emovu)13.10. iMotions A/S13.11. sensation.io13.12. RealComm Global LLC13.13. Neuromore Inc.13.14. Lightspeed LLC13.15. Retinad Virtual Reality Inc.

For more information about this report visit https://www.researchandmarkets.com/r/w9ka7x

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

http://www.researchandmarkets.com

Original post:
Emotional Analytics Industry to Exhibit a CAGR of 15.6% During 2019-2027 - Biometrics & Neuroscience Technologies are Leading the Market -...

Neuromodulation Is the Secret Sauce for This Adaptive, Fast-Learning AI – Singularity Hub

As obstinate and frustrating as we are sometimes, humans in general are pretty flexible when it comes to learningespecially compared to AI.

Our ability to adapt is deeply rooted within our brains chemical base code. Although modern AI and neurocomputation have largely focused on loosely recreating the brains electrical signals, chemicals are actually the prima donna of brain-wide neural transmission.

Chemical neurotransmitters not only allow most signals to jump from one neuron to the next, they also feedback and fine-tune a neurons electrical signals to ensure theyre functioning properly in the right contexts. This process, traditionally dubbed neuromodulation, has been front and center in neuroscience research for many decades. More recently, the idea has expanded to also include the process of directly changing electrical activity through electrode stimulation rather than chemicals.

Neural chemicals are the targets for most of our current medicinal drugs that re-jigger brain functions and states, such as anti-depressants or anxiolytics. Neuromodulation is also an immensely powerful way for the brain to flexibly adapt, which is why its perhaps surprising that the mechanism has rarely been explicitly incorporated into AI methods that mimic the brain.

This week, a team from the University of Liege in Belgium went old school. Using neuromodulation as inspiration, they designed a new deep learning model that explicitly adopts the mechanism to better learn adaptive behaviors. When challenged on a difficult navigational task, the team found that neuromodulation allowed the artificial neural net to better adjust to unexpected changes.

For the first time, cognitive mechanisms identified in neuroscience are finding algorithmic applications in a multi-tasking context. This research opens perspectives in the exploitation in AI of neuromodulation, a key mechanism in the functioning of the human brain, said study author Dr. Damien Ernst.

Neuromodulation often appears in the same breath as another jargon-y word, neuroplasticity. Simply put, they just mean that the brain has mechanisms to adapt; that is, neural networks are flexible or plastic.

Cellular neuromodulation is perhaps the grandfather of all learning theories in the brain. Famed Canadian psychologist and father of neural networks Dr. Donald Hebb popularized the theory in the 1900s, which is now often described as neurons that fire together, wire together. On a high level, Hebbian learning summarizes how individual neurons flexibly change their activity levels so that they better hook up into neural circuits, which underlie most of the brains computations.

However, neuromodulation goes a step further. Here, neurochemicals such as dopamine dont necessarily directly help wire up neural connections. Rather, they fine-tune how likely a neuron is to activate and link up with its neighbor. These so-called neuromodulators are similar to a temperature dial: depending on context, they either alert a neuron if it needs to calm down so that it only activates when receiving a larger input, or hype it up so that it jumps into action after a smaller stimuli.

Cellular neuromodulation provides the ability to continuously tune neuron input/output behaviors to shape their response to external stimuli in different contexts, the authors wrote. This level of adaptability especially comes into play when we try things that need continuous adjustments, such as how our feet strike uneven ground when running, or complex multitasking navigational tasks.

To be very clear, neuromodulation isnt directly changing synaptic weights. (Ughwhat?)

Stay with me. You might know that a neural network, either biological or artificial, is a bunch of neurons connected to each other through different strengths. How readily one neuron changes a neighboring neurons activityor how strongly theyre linkedis often called the synaptic weight.

Deep learning algorithms are made up of multiple layers of neurons linked to each other through adjustable weights. Traditionally, tweaking the strengths of these connections, or synaptic weights, is how a deep neural net learns (for those interested, the biological equivalent is dubbed synaptic plasticity).

However, neuromodulation doesnt directly act on weights. Rather, it alters how likely a neuron or network is to be capable of changing their connectionthat is, their flexibility.

Neuromodulation is a meta-level of control; so its perhaps not surprising that the new algorithm is actually composed of two separate neural networks.

The first is a traditional deep neural net, dubbed the main network. It processes input patterns and uses a custom method of activationhow likely a neuron in this network is to spark to life depends on the second network, or the neuromodulatory network. Here, the neurons dont process input from the environment. Rather, they deal with feedback and context to dynamically control the properties of the main network.

Especially important, said the authors, is that the modulatory network scales in size with the number of neurons in the main one, rather than the number of their connections. Its what makes the NMN different, they said, because this setup allows us to extend more easily to very large networks.

To gauge the adaptability of their new AI, the team pitted the NMN against traditional deep learning algorithms in a scenario using reinforcement learningthat is, learning through wins or mistakes.

In two navigational tasks, the AI had to learn to move towards several targets through trial and error alone. Its somewhat analogous to you trying to play hide-and-seek while blindfolded in a completely new venue. The first task is relatively simple, in which youre only moving towards a single goal and you can take off your blindfold to check where you are after every step. The second is more difficult in that you have to reach one of two marks. The closer you get to the actual goal, the higher the rewardcandy in real life, and a digital analogy for AI. If you stumble on the other, you get punishedthe AI equivalent to a slap on the hand.

Remarkably, NMNs learned both faster and better than traditional reinforcement learning deep neural nets. Regardless of how they started, NMNs were more likely to figure out the optimal route towards their target in much less time.

Over the course of learning, NMNs not only used their neuromodulatory network to change their main one, they also adapted the modulatory networktalk about meta! It means that as the AI learned, it didnt just flexibly adapt its learning; it also changed how it influences its own behavior.

In this way, the neuromodulatory network is a bit like a library of self-help booksyou dont just solve a particular problem, you also learn how to solve the problem. The more information the AI got, the faster and better it fine-tuned its own strategy to optimize learning, even when feedback wasnt perfect. The NMN also didnt like to give up: even when already performing well, the AI kept adapting to further improve itself.

Results show that neuromodulation is capable of adapting an agent to different tasks and that neuromodulation-based approaches provide a promising way of improving adaptation of artificial systems, the authors said.

The study is just the latest in a push to incorporate more biological learning mechanisms into deep learning. Were at the beginning: neuroscientists, for example, are increasingly recognizing the role of non-neuron brain cells in modulating learning, memory, and forgetting. Although computational neuroscientists have begun incorporating these findings into models of biological brains, so far AI researchers have largely brushed them aside.

Its difficult to know which brain mechanisms are necessary substrates for intelligence and which are evolutionary leftovers, but one thing is clear: neuroscience is increasingly providing AI with ideas outside its usual box.

Image Credit: Image by Gerd Altmann from Pixabay

View original post here:
Neuromodulation Is the Secret Sauce for This Adaptive, Fast-Learning AI - Singularity Hub

Cancer cure, fascination for biology, neuroscience what drew these women to science – ThePrint

Text Size:A- A+

New Delhi: On 22 December 2015, the United Nations General Assembly declared 11 February as the International Day of Women and Girls in Science as part of its resolution Transforming our world: the 2030 Agenda for Sustainable Development.

Meant to promote complete and equal access for women and girls to the sciences, it is celebrated by UNESCO and UN-Women in collaboration with other institutions.

Currently, less than 30 per cent of researchers worldwide are women and according to UNESCO data from 2014 2016, only around 30 per cent of female students select STEM-related fields in higher education. The world over, female students enrolment is particularly low with only 5 per cent opting for natural science, maths or statistics, only 3 per cent women opting for information and communication technology and 8 per cent opting for manufacturing and construction.

In India, the Ministry of Science and Technology has a special Women Scientist Scheme, which provides fellowships and research grants to enable women to re-enter the field as well as provide a launch pad for them into the field. Aside from this, the Ministry also started the Vigyan Joshi programme in October 2018 to encourage girls from rural areas to opt for any subject in science, engineering and technology. Through the programme, students met scientists from NASA and even got a scholarship of Rs 5,000 after completion of the programme.

On International Day of Women and Girls in Science, ThePrint speaks to women and girls in the field of science about their choices, struggles, and journey.

Neharika Ann Mann, who is about to take her class 12 board exams opted for science in class 11, taking physics, chemistry, biology and maths as her main subjects. However for this 17-year-old, the dream of entering the world of science began very early on.

She said, It was in class 3 that a close friends relative died of cancer. It was then that I decided that I would find a cure to cancer. That thought has evolved and I have now decided to eventually study pharmacology, which is a branch of medicine concerned with the uses, effects and modes of action of drugs.

Neharika plans to apply to Delhi University and because she was advised not to specialise too soon, wants to study biochemistry first, before specialising.

With no one else from her family working in the field of science, Neharika explains that it is the very fact that the stream enables her to think out of the box that attracts her most to the world of science.

She said, In ICSE science, there is a lot of pressure and we often feel as though we have to mug up theories. However the reality is that you need to keep finding things that interest you and ask questions that a science textbook will not give you.

Also read: CERN scientist Archana Sharma says Indian girls need more female role models in STEM

Manya Singh was fascinated by biology in school. Physics and chemistry did not excite her as much because she could relate more to biology as she could observe many aspects of it in her surroundings.

After graduating, Singh studied botany from Ramjas College, Delhi University. She tells ThePrint, It was during my undergraduation that I studied flora and fauna even further, and when I zeroed in on my interest in ecology and also where I felt the urge to do fieldwork.

Singh then enrolled for a Masters in ecology and environmental sciences from Nalanda University, which is where she ultimately focused on climate change and conservation studies. Unwilling to only be restricted to the classroom, she decided to work in the field as well. Her fieldwork took her to Gujarat, where she worked at the states forest department, focusing on agro-forestry for commercial use. She then moved to Dehradun, where she is currently based. At the Centre for Ecology, Development and Research, she works with mountain communities across the state to focus on springwater and glacial conservation.

While in the field, she noticed the skewed gender ratio. She noted that in research positions or in her Masters, the gender ratio was fairly equal, but in the field its only men. There is an astounding lack of women out there in the field. Be it as project leads or in state forest departments or ministries such as for water resources. There are barely any women. It is what I have to encounter and witness every day.

Singh also led the climate strike in Dehradun and hopes to eventually apply for a PhD on methods of water conservation.

Vidita Vaidya, is a neuroscientist and professor at the Tata Institute of Fundamental Research in Mumbai, a National Centre of the Government of India, under the umbrella of the Department of Atomic Energy. Vaidyas primary areas of interest are neuroscience and molecular psychiatry.

Having got her neuroscience doctoral degree from Yale and postdoctorate from the Karolinska Institute in Sweden and from Oxford, Vaidya joined TIFR in 2000 as a principal investigator.

She studies parts of the brain that regulate emotion and monitors how these mechanisms are influenced by life experiences. Vaidya also investigates how changes in the brain form the basis of psychiatric disorders like depression and how early life experiences contribute to alterations in behaviour.

Speaking to ThePrint, Vaidya explains that it is hard for young women who want to become a faculty member at an institution for science in India.

She underscored the need for more diversity in such institutions and explained how cutthroat and ruthless the scientific community can be with its high levels of competition.

Vaidya is however quick to acknowledge government schemes that encourage more women to enter the field, creche facilities and the progressive maternal leave policy. She noted, I am where I am because I have a supportive family, be it my family structure, in-laws or spouse, and therefore do not face the standard challenges.

With the same goal of achieving success in their respective fields these women are determined to change the world of science in their own way.

Also read: These forgotten women played a huge role in eradicating smallpox from India

ThePrint is now on Telegram. For the best reports & opinion on politics, governance and more, subscribe to ThePrint on Telegram.

See the rest here:
Cancer cure, fascination for biology, neuroscience what drew these women to science - ThePrint

Neuroscience Antibodies & Assays Market Increasing Demand with Leading Player, Comprehensive Analysis, Forecast 2026 – Jewish Life News

The Neuroscience Antibodies & Assays Market report 2020-2026 provides a comprehensive analysis of the current market for Smart Camera. It determines the market size of Neuroscience Antibodies & Assays and also determines the factors that control market growth. The report begins with a basic overview of the Neuroscience Antibodies & Assays industry and then goes into the Details of the Neuroscience Antibodies & Assays market.

Neuroscience Antibodies & Assays Market was valued at USD 2.42 Billion in 2018 and is projected to reach USD 5.14 Billion by 2026, growing at a CAGR of 9.7% from 2019 to 2026.

The Neuroscience Antibodies & Assays market report provides detailed information on key factors, Opportunities, Challenges, industry trends and their impact on the market. The market report Neuroscience Antibodies & Assays also includes company data and its operation. This report also contains information about the pricing strategy, brand strategy and target customer of the Neuroscience Antibodies & Assays market. It also provides the distributors/dealer list offered by the company. This research report also deals with the main competition, the market development with forecast of the expected years and the expected growth rates. The main factors that drive and influence growth market data and analysis come from a combination of primary and secondary sources.

Get | Download Sample Copy @https://www.verifiedmarketresearch.com/download-sample/?rid=28342&utm_source=JLN&utm_medium=002

[Note: our free sample report provides a brief introduction to the table of contents, table of contents, list of tables and figures, competitive landscape and geographic segmentation, as well as innovations and future developments based on research methods.]

The top Manufacturer with company profile, sales volume, and product specifications, revenue (Million/Billion USD) and market share

Global Neuroscience Antibodies & Assays Market Competitive Insights

The competitive analysis serves as a bridge between manufacturers and other participants that are available on the Neuroscience Antibodies & Assays Market. The report includes a comparative study of Top market players with company profiles of competitive companies, Neuroscience Antibodies & Assays Market product innovations and cost structure, production sites and processes, sales details of past years and technologies used by them. The Neuroscience Antibodies & Assays Market report also explains the main strategies of competitors, their SWOT analysis and how the competition will react to changes in marketing techniques. In this report, the best market research techniques were used to provide the latest knowledge about Neuroscience Antibodies & Assays Market to competitors in the market.

Global Neuroscience Antibodies & Assays Market Segmentation information

The report provides important insights into the various market segments presented to simplify the assessment of the global Neuroscience Antibodies & Assays Market. These market segments are based on several relevant factors, including Neuroscience Antibodies & Assays Market product type or services, end users or applications and regions. The report also includes a detailed analysis of the regional potential of the Neuroscience Antibodies & Assays Market, which includes the difference between production values and demand volumes, as well as the presence of market participants and the growth of each Region over the given forecast period

Ask For Discount (Exclusive Offer) @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=28342&utm_source=JLN&utm_medium=002

Neuroscience Antibodies & Assays Market: Regional Analysis :

As part of regional analysis, important regions such as North America, Europe, the MEA, Latin America, and Asia Pacific have been studied. The regional Neuroscience Antibodies & Assays markets are analyzed based on share, growth rate, size, production, consumption, revenue, sales, and other crucial factors. The report also provides country-level analysis of the Neuroscience Antibodies & Assays industry.

Table of Contents

Introduction: The report starts off with an executive summary, including top highlights of the research study on the Neuroscience Antibodies & Assays industry.

Market Segmentation: This section provides detailed analysis of type and application segments of the Neuroscience Antibodies & Assays industry and shows the progress of each segment with the help of easy-to-understand statistics and graphical presentations.

Regional Analysis: All major regions and countries are covered in the report on the Neuroscience Antibodies & Assays industry.

Market Dynamics: The report offers deep insights into the dynamics of the Neuroscience Antibodies & Assays industry, including challenges, restraints, trends, opportunities, and drivers.

Competition: Here, the report provides company profiling of leading players competing in the Neuroscience Antibodies & Assays industry.

Forecasts: This section is filled with global and regional forecasts, CAGR and size estimations for the Neuroscience Antibodies & Assays industry and its segments, and production, revenue, consumption, sales, and other forecasts.

Recommendations: The authors of the report have provided practical suggestions and reliable recommendations to help players to achieve a position of strength in the Neuroscience Antibodies & Assays industry.

Research Methodology: The report provides clear information on the research approach, tools, and methodology and data sources used for the research study on the Neuroscience Antibodies & Assays industry.

What will you find out from the global Neuroscience Antibodies & Assays Market Report?

The report contains statistical analyses of the current and future Status of the global Neuroscience Antibodies & Assays Market with a forecast to 2026.The report contains detailed information on manufacturers, Neuroscience Antibodies & Assays Market raw material suppliers and buyers with their trade outlook for 2020-2026.The report informs you about the most important drivers, technologies and Trends that will shape the global Neuroscience Antibodies & Assays Market in the near future.The report added an exclusive market segmentation, broken down by Product Type, Neuroscience Antibodies & Assays Market end user and Region.The strategic perspectives on Neuroscience Antibodies & Assays Market Dynamics, current production process and applications.

Complete Report is Available @ https://www.verifiedmarketresearch.com/product/Neuroscience-Antibodies-&-Assays-Market/?utm_source=JLN&utm_medium=002

About Us:

Verified market research partners with clients to provide insight into strategic and growth analytics; data that help achieve business goals and targets. Our core values include trust, integrity, and authenticity for our clients.

Our research studies help our clients to make superior data-driven decisions, capitalize on future opportunities, optimize efficiency and keeping them competitive by working as their partner to deliver the right information without compromise.

Contact Us:

Mr. Edwyne FernandesCall: +1 (650) 781 4080Email:[emailprotected]

Read more from the original source:
Neuroscience Antibodies & Assays Market Increasing Demand with Leading Player, Comprehensive Analysis, Forecast 2026 - Jewish Life News

MRI Analysis Tries To Make Sense of the Senses – Technology Networks

If we cross a road with our smartphone in view, a car horn or engine noise will startle us. In everyday life we can easily combine information from different senses and shift our attention from one sensory input to another for example, from seeing to hearing. But how does the brain decide which of the two senses it will focus attention on when the two interact? And, are these mechanisms reflected in the structure of the brain?To answer these questions, scientists at the Max Planck Institute for Human Cognitive and Brain Sciences (MPI CBS) in Leipzig and the Computational Neuroscience and Cognitive Robotics Centre at the University of Birmingham measured how sensory stimuli are processed in the brain. In contrast to previous studies, they did not restrict their observations to the surface the cerebral cortex. For the first time, they also measured the sensory signals at different depths in the cortex. The researchers' findings suggest that our brains conduct the multi-sensory flow of information via distinct circuits right down to the smallest windings of this highly folded brain structure.

While the participants in their study were lying in a magnetic resonance tomograph (MRI), the scientists showed them visual symbols on a screen while simultaneously playing sounds. In a prior condition, the participants had been asked to explicitly focus their attention on either the audible or visible aspect of the stimuli. The neurophysicists Robert Turner, Robert Trampel and Rmi Gau then analyzed at which exact points the sensory stimuli were being processed. Two challenges needed to be overcome. "The cerebral cortex is only two to three millimeters thick. So we needed a very high spatial resolution (of less than one millimeter) during data acquisition," explains Trampel, who co-directed the study at the MPI CBS. "Also, due to the dense folding of the cerebral cortex, we had to digitally smooth it and break it down into different layers, in order to be able to precisely locate the signals. This was all done on a computer of course."

The results showed that when participants heard a sound, visual areas of their brains were largely switched off. This happened regardless of whether they focused on the audible or visible aspect of the stimuli. However, if they strongly attended to the auditory input, brain activity decreased, particularly in the regions representing the center of the visual field. Thus, it seems that sound can strongly draw our attention away from what we're looking at.

In auditory brain regions the researchers also observed, for the first time, that the activity pattern, across different cortical layers, changed when participants were presented with only sounds. The situation was different when participants only perceived "something to the eye": in that case there was no change. Gau sums up, "So when we have to process different sensory impressions at the same time, different neuron circuits become active, depending on what we focus our attention on. We have now been able to make these interactions visible through novel computerized experiments."ReferenceGau et al. (2020) Resolving multisensory and attentional influences across cortical depth in sensory cortices. eLIFE. DOI: https://doi.org/10.7554/eLife.46856

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

Original post:
MRI Analysis Tries To Make Sense of the Senses - Technology Networks

Cheap Diuretic Pill Could Help With Autism Symptoms, New Findings Suggest – Technology Networks

It is possible to improve symptoms in autistic children with a cheap generic drug, ourlatest study shows. The drug, bumetanide, is widely used to treat high blood pressure and swelling, and it costsno more than 10for a months supply of pills.

Autism is a neurodevelopmental disorder which is more common in boys than girls. According to the World Health Organization,1%-2% of people have the condition.

Autism can be diagnosed as early as two years old or even at 18 months. Children with moderate or severe autism can find social situations difficult. They may not make eye contact with their parents or take part in cooperative play and conversation. They may also show repetitive behaviour and have an intense interest in objects. This behaviour not only affects engagement in family activities but can also make it harder for them to make friends at school.

We were motivated to test bumetanide as a result ofbackground findingswhich suggested that the drug changed important brain chemicals in mouse models of autism; and also by somestudies, including in autistic teenagers, showing that bumetanide may have beneficial effects.

Our research group, an international collaboration between researchers at several institutions in China and the University of Cambridge, wanted to focus on young children with moderate and severe autism and to test whether bumetanide could improve their symptoms. We also wanted to understand the mechanism by which the drug achieved this. Understanding how bumetanide worked could lead to future drug development to treat moderate and severe autism.

There were 81 children with moderate to severe autism in our study 42 in the bumetanide group, who received 0.5mg of bumetanide twice a day for three months; and 39 children in the control group, who received no treatment. The children were three to six years of age.

Some of the children had their brains scanned using magnetic resonance spectroscopy (MRS) 38 in the bumetanide group and 17 in the control group. MRS is a non-invasive way of measuring chemicals in the brain. For our study, we measured brain chemicals called GABA and glutamate, which are important for learning and brain plasticity (the brains ability to change and adapt as a result of experience).

In the bumetanide group, autism symptoms improved as measured by the childhood autism rating scale (CARS) and also by a doctors overall impression. The doctors who were assessing symptom change were blind to treatment that is, they were unaware of who was receiving bumetanide. Improvements in symptoms were associated with changes in the brain chemicals GABA/glutamate ratios and, in particular, with decreases in GABA.

Looking specifically at what improved on the rating scale, we found decreases in repetitive behaviour and decreased interest in objects. These reductions in unsociable behaviour allow more time for increases in social behaviour.

One of the mothers of a four-year-old boy, living in a rural area outside Shanghai, said that her child, who was in the bumetanide group, became better at making eye contact with family members and relatives and was able to take part in more family activities.

We also found that the drug is safe for young autistic children and has no significant side-effects. Bumetanide could improve the quality of life and wellbeing of autistic children. Existing treatments are predominantly behavioural, including Applied Behaviour Analysis or ABA. Most families, particularly those in rural areas, will have limited or no access to these treatments, which are generally only available in specialised centres. The use of bumetanide would mean that there would even be a treatment for autistic children living in rural areas.

This study is important and exciting because bumetanide can improve social learning and reduce autism symptoms when the brains of these children are still developing. We now know that human brains are still in development until late adolescence and early adulthood. Further research is now needed to confirm the effectiveness of bumetanide in treating autism.

Barbara Jacquelyn Sahakian, Professor of Clinical Neuropsychology,University of CambridgeandChristelle Langley, Postdoctoral Research Associate, Cognitive Neuroscience,University of Cambridge

This article is republished fromThe Conversationunder a Creative Commons license. Read theoriginal article.

Read more here:
Cheap Diuretic Pill Could Help With Autism Symptoms, New Findings Suggest - Technology Networks